Glaxo's Breo lung drug trial fails to show it extends life
9th Sep 2015 07:18
(ShareCast News) - Initial results of GlaxoSmithKline and Theravance's study to understand mortality on the Breo Ellipta inhaler for the treatment of chronic obtrusive pulmonary disease showed that it failed to prolong the life of patients. In a clinical trial of 16,485 patients from 43 countries, p
Read moreBroker tips: DMGT, Pearson, GSK
7th Sep 2015 13:29
(ShareCast News) - Exane BNP Paribas downgraded Daily Mail & General Trust to 'neutral' from 'outperform' and cut its price target to 850p from 920p. It noted the stock's recent rebound, which has seen it outperform the media sector by around 10% in the last month following a precipitous drop in Jul
Read moreGSK gains as Merrill hikes rating on valuation and dividend yield
7th Sep 2015 09:57
(ShareCast News) - Bank of America Merrill Lynch upgraded GlaxoSmithKline to 'neutral' from 'underperform' with an unchanged price target of 1,450p. It noted that the stock is now trading around 18% off its April highs and 8% below the bank's price target, offering approximately 14% total return wit
Read moreGSK extends Novartis disposal agreement
21st Aug 2015 07:27
(ShareCast News) - GlaxoSmithKline has sold all the rights to its ofatumumab drug to Novartis for up to £1.03bn, extending a previous disposal agreement. GSK previously agreed to divest the drug's oncology indications and has now agreed to include its rights in ofatumumab for auto-immune indications
Read moreLondon pre-open: stocks set to plunge as China off the rails
21st Aug 2015 07:20
(ShareCast News) - City sources predict the FTSE 100 will open 142 points lower than Thursday's close of 6,367.89. "European equities are set to plunge on the open as China goes off the rails," London Capital Group night dealer Jonathan Sudaria said. Sudaria said bulls were already slowed by a barr
Read moreLondon pre-open: Europe likely to follow the US lower
4th Aug 2015 08:07
(ShareCast News) - City sources predict the FTSE 100 will open 25 points lower than Monday's close of 6,688.62. Overnight markets were mixed with the US down and Asia up, but Europe has followed the US, London Capital Group night editor Jonathan Sudaria said. "Gains in Asia, and in particular
Read moreFTSE 100 movers: GSK and Hikma lead blue chips higher
29th Jul 2015 15:24
(ShareCast News) - The FTSE 100 index built an early lead on Wednesday and stayed in positive territory thanks to forecast-busting results from several heavyweights in the pharma, tobacco and banking sectors. London's blue chip index was up 0.57% to 6,592.54 at 1435 BST. Top of the leaderboard mid-
Read moreGlaxoSmithKline rallies as second-quarter earnings beat estimates
29th Jul 2015 13:09
(ShareCast News) - Shares in GlaxoSmithKline rallied after the pharmaceutical company posted better-than-expected second-quarter earnings and operating profits, and said it expects to see a significant recovery in core earnings per share next year. Sales for the period were up 6% at £5.9bn, while co
Read moreMonday tips round-up: Royal Dutch Shell, BP, GSK and Anglo American
27th Jul 2015 11:45
(ShareCast News) - There is an inevitable dividend question hanging over the two big oil companies, the Times' Tempus column said. Royal Dutch Shell and BP, both reporting this week, offer among the best yields in the market, in excess of 6%. If the payments are maintained, they remain attractive i
Read moreLondon open: FTSE 100 resilient in face of weak China, Eurozone PMIs
24th Jul 2015 09:19
(ShareCast News) - Investors braved weaker than expected readings on Chinese and Eurozone manufacturing and lingering worries regarding Greece, allowing the top flight index to recover after dipping at the start of trading. As of 09:05 the Footsie was 7.34 points higher to end at 6,665.30. Stocks r
Read moreGlaxo's malaria vaccine clears final scientific hurdle
24th Jul 2015 09:03
(ShareCast News) - Healthcare giant GlaxoSmithKline said its malaria vaccine has passed its last scientific hurdle, although the immunisation programme in sub-Saharan Africa could be still over 12 months away. On Thursday, the treatment, aimed at young children, was given a positive scientific opini
Read moreTuesday share tips: Sky, BG Group, Vodafone
30th Jun 2015 12:02
Sky´s decision to dedicate one of its channels solely to Formula 1 fits in well with its strategy as a content distributor, but a theoretical purchase of the franchise whole does not. Speculation has surfaced it might do just that, with Liberty Global and a group backed by the Qatari government also
Read moreBroker tips: GlaxoSmithKline, Astrazeneca, Hikma, Shire, Petrofac, ARM Holdings
26th Jun 2015 11:39
HSBC initiated coverage of the European pharmaceuticals, saying the re-rating over the last few years looks set to continue. In terms of UK stocks, it initiated GlaxoSmithKline at 'buy' with a 1,700p price target, and AstraZeneca and Hikma Pharmaceuticals at 'hold' with 4,640p and 1,936p price targe
Read moreLiberum upgrades GlaxoSmithKline to 'hold'
26th Jun 2015 10:33
Liberum upgraded GlaxoSmithKline to 'hold' from 'sell', but cut the price target to 1,350p from 1,400p. "Somewhat counter-intuitively, we believe a dividend cut is increasingly likely and necessary and therefore we upgrade," said Liberum. "With the recent fall in the share and the increasing likeli
Read moreFriday broker round-up
26th Jun 2015 10:11
ARM Holdings: Bernstein downgrades to underperform. GlaxoSmithKline: Liberum ups view to hold from sell. HSBC initiates coverage at buy with 1,700p target. AztraZeneca: HSBC initiates coverage at hold with 4,640p target. Qinetiq: UBS downgrades to sell from neutral. Meggitt: UBS raises view to ne
Read more